Hamaguchi, Tetsuya <br/><br/>
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.  [electronic resource] 

 -  Cancer science  Nov 2019 
 - 3565-3572 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1349-7006 
<br/><br/><label>Standard No.: </label>10.1111/cas.14198  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Asian People<br/>Biomarkers, Tumor--blood<br/>Camptothecin--analogs & derivatives<br/>Colonic Neoplasms--blood<br/>Fluorouracil--therapeutic use<br/>Humans<br/>Insulin-Like Growth Factor Binding Protein 1--blood<br/>Interleukin-8--blood<br/>Japan<br/>Kallikreins--blood<br/>Leucovorin--therapeutic use<br/>Placenta Growth Factor--blood<br/>Prognosis<br/>Progression-Free Survival<br/>Prospective Studies<br/>Pulmonary Surfactant-Associated Protein D--blood<br/>Receptor for Advanced Glycation End Products--blood<br/>Receptors, Tumor Necrosis Factor, Type II--blood<br/>Receptors, Vascular Endothelial Growth Factor--therapeutic use<br/>Recombinant Fusion Proteins--therapeutic use<br/>Rectal Neoplasms--blood<br/>Regression Analysis<br/>Tenascin--blood<br/>Tissue Inhibitor of Metalloproteinase-1--blood<br/>Vascular Endothelial Growth Factor Receptor-1--blood